Physician profile
Daniel W Marks
NPI 1871906420
$891.55
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.27 · 2020: $82.52 · 2021: $299 · 2022: $329 · 2023: $48.65 · 2024: $38.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.54 | 2021-2022 | |
| Hologic Sales and Service, LLC | $152.91 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Intuitive Surgical, INC. | $92.26 | 2022 | |
| Organon LLC | $81.01 | 2021-2024 | |
| Therapeuticsmd, INC. | $75.48 | 2019-2022 | |
| Roche Diagnostics Corporation | $42.04 | 2020 | |
| Avion Pharmaceuticals | $31.37 | 2019-2021 | |
| Allergan, INC. | $28.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.49 | 2021-2022 | |
| Ethicon US, LLC | $20.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2022 | |
| Pfizer INC. | $19.30 | 2021 | |
| Coloplast Corp | $18.53 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $16.96 | 2022 | |
| Mayne Pharma Commercial LLC | $12.81 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.